<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Pathog</journal-id><journal-id journal-id-type="iso-abbrev">PLoS Pathog</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plospath</journal-id><journal-title-group><journal-title>PLoS Pathogens</journal-title></journal-title-group><issn pub-type="ppub">1553-7366</issn><issn pub-type="epub">1553-7374</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4944956</article-id><article-id pub-id-type="pmid">27415008</article-id><article-id pub-id-type="doi">10.1371/journal.ppat.1005761</article-id><article-id pub-id-type="publisher-id">PPATHOGENS-D-16-00532</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Blood Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>T Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>T Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>T Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>T Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Blood cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>T cells</subject><subj-group><subject>Memory T cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>T cells</subject><subj-group><subject>Memory T cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>T cells</subject><subj-group><subject>Memory T cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>T cells</subject><subj-group><subject>Memory T cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Cognitive Science</subject><subj-group><subject>Cognition</subject><subj-group><subject>Memory</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Learning and Memory</subject><subj-group><subject>Memory</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Virology</subject><subj-group><subject>Viral Persistence and Latency</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and Immunization</subject><subj-group><subject>Antiviral Therapy</subject><subj-group><subject>Antiretroviral Therapy</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and Immunization</subject><subj-group><subject>Antiviral Therapy</subject><subj-group><subject>Antiretroviral Therapy</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Public and Occupational Health</subject><subj-group><subject>Preventive Medicine</subject><subj-group><subject>Vaccination and Immunization</subject><subj-group><subject>Antiviral Therapy</subject><subj-group><subject>Antiretroviral Therapy</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Molecular Biology</subject><subj-group><subject>Molecular Biology Techniques</subject><subj-group><subject>Cloning</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Molecular Biology Techniques</subject><subj-group><subject>Cloning</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Infectious diseases</subject><subj-group><subject>Viral diseases</subject><subj-group><subject>HIV infections</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="running-head">Immune Checkpoints and HIV Persistence during ART</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fromentin</surname><given-names>Rémi</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bakeman</surname><given-names>Wendy</given-names></name><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lawani</surname><given-names>Mariam B.</given-names></name><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Khoury</surname><given-names>Gabriela</given-names></name><xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref><xref ref-type="aff" rid="aff004">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hartogensis</surname><given-names>Wendy</given-names></name><xref ref-type="aff" rid="aff005">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>DaFonseca</surname><given-names>Sandrina</given-names></name><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Killian</surname><given-names>Marisela</given-names></name><xref ref-type="aff" rid="aff006">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Epling</surname><given-names>Lorrie</given-names></name><xref ref-type="aff" rid="aff006">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hoh</surname><given-names>Rebecca</given-names></name><xref ref-type="aff" rid="aff006">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sinclair</surname><given-names>Elizabeth</given-names></name><xref ref-type="aff" rid="aff006">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hecht</surname><given-names>Frederick M.</given-names></name><xref ref-type="aff" rid="aff006">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bacchetti</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="aff005">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Deeks</surname><given-names>Steven G.</given-names></name><xref ref-type="aff" rid="aff006">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lewin</surname><given-names>Sharon R.</given-names></name><xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref><xref ref-type="aff" rid="aff004">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sékaly</surname><given-names>Rafick-Pierre</given-names></name><xref ref-type="aff" rid="aff007">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chomont</surname><given-names>Nicolas</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff008">
<sup>8</sup>
</xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001">
<label>1</label>
<addr-line>Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Montreal, Quebec, Canada</addr-line>
</aff><aff id="aff002">
<label>2</label>
<addr-line>Vaccine and Gene Therapy Institute Florida, Port St Lucie, Florida, United States of America</addr-line>
</aff><aff id="aff003">
<label>3</label>
<addr-line>Department of Infectious Diseases, Monash University and Alfred Hospital, Melbourne, Victoria, Australia</addr-line>
</aff><aff id="aff004">
<label>4</label>
<addr-line>The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Victoria, Australia</addr-line>
</aff><aff id="aff005">
<label>5</label>
<addr-line>Department of Epidemiology and Biostatistics, University of California, San Francisco, California, United States of America</addr-line>
</aff><aff id="aff006">
<label>6</label>
<addr-line>Department of Medicine, University of California, San Francisco, California, United States of America</addr-line>
</aff><aff id="aff007">
<label>7</label>
<addr-line>Case Western Reserve University, Cleveland, Ohio, United States of America</addr-line>
</aff><aff id="aff008">
<label>8</label>
<addr-line>Department of Microbiology, Infectiology, and Immunology, Université de Montréal, Faculty of Medicine, Montreal, Quebec, Canada</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Douek</surname><given-names>Daniel C.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>Vaccine Research Center, UNITED STATES</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><text><SENT sid="1" pm="."><plain>The authors have declared that no competing interests exist. </plain></SENT>
</text></p></fn><fn fn-type="con" id="contrib001"><p><text><SENT sid="2" pm="."><plain>Conceived and designed the experiments: RF SGD SRL RPS NC. </plain></SENT>
<SENT sid="3" pm="."><plain>Performed the experiments: RF WB MBL GK SD MK. </plain></SENT>
<SENT sid="4" pm="."><plain>Analyzed the data: RF WH PB MK LE RH ES FMH. </plain></SENT>
<SENT sid="5" pm="."><plain>Wrote the paper: RF PB SGD SRL RPS NC. </plain></SENT>
</text></p></fn><corresp id="cor001">* E-mail: <email>nicolas.chomont@umontreal.ca</email></corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>7</month><year>2016</year></pub-date><pub-date pub-type="collection"><month>7</month><year>2016</year></pub-date><volume>12</volume><issue>7</issue><elocation-id>e1005761</elocation-id><history><date date-type="received"><day>7</day><month>3</month><year>2016</year></date><date date-type="accepted"><day>20</day><month>6</month><year>2016</year></date></history><permissions><copyright-statement>© 2016 Fromentin et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Fromentin et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="ppat.1005761.pdf"/><related-article id="d35e816" related-article-type="companion" ext-link-type="doi" xlink:href="10.1371/journal.ppat.1005661">
<article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Exhaustion of Activated CD8 T cells Predicts Disease Progression in Primary HIV-1 Infection </plain></SENT>
</text></SecTag></article-title>
</related-article><abstract><p><SecTag type="ABS"><text><SENT sid="1" pm="."><plain>HIV persists in a small pool of latently infected cells despite antiretroviral therapy (ART). </plain></SENT>
<SENT sid="2" pm="."><plain>Identifying cellular markers expressed at the surface of these cells may lead to novel therapeutic strategies to reduce the size of the HIV reservoir. </plain></SENT>
<SENT sid="3" pm="."><plain>We hypothesized that CD4+ T cells expressing immune checkpoint molecules would be enriched in HIV-infected cells in individuals receiving suppressive ART. </plain></SENT>
<SENT sid="4" pm="."><plain>Expression levels of 7 immune checkpoint molecules (PD-1, CTLA-4, LAG-3, TIGIT, TIM-3, CD160 and 2B4) as well as 4 markers of HIV persistence (integrated and total HIV DNA, 2-LTR circles and cell-associated unspliced HIV RNA) were measured in PBMCs from 48 virally suppressed individuals. </plain></SENT>
<SENT sid="5" pm="."><plain>Using negative binomial regression models, we identified PD-1, TIGIT and LAG-3 as immune checkpoint molecules positively associated with the frequency of CD4+ T cells harboring integrated HIV DNA. </plain></SENT>
<SENT sid="6" pm="."><plain>The frequency of CD4+ T cells co-expressing PD-1, TIGIT and LAG-3 independently predicted the frequency of cells harboring integrated HIV DNA. </plain></SENT>
<SENT sid="7" pm="."><plain>Quantification of HIV genomes in highly purified cell subsets from blood further revealed that expressions of PD-1, TIGIT and LAG-3 were associated with HIV-infected cells in distinct memory CD4+ T cell subsets. </plain></SENT>
<SENT sid="8" pm="."><plain>CD4+ T cells co-expressing the three markers were highly enriched for integrated viral genomes (median of 8.2 fold compared to total CD4+ T cells). </plain></SENT>
<SENT sid="9" pm="."><plain>Importantly, most cells carrying inducible HIV genomes expressed at least one of these markers (median contribution of cells expressing LAG-3, PD-1 or TIGIT to the inducible reservoir = 76%). </plain></SENT>
<SENT sid="10" pm="."><plain>Our data provide evidence that CD4+ T cells expressing PD-1, TIGIT and LAG-3 alone or in combination are enriched for persistent HIV during ART and suggest that immune checkpoint blockers directed against these receptors may represent valuable tools to target latently infected cells in virally suppressed individuals. </plain></SENT>
</text></SecTag></p></abstract><abstract abstract-type="summary"><title><text><SENT sid="11" pm="."><plain>Author Summary </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="12" pm="."><plain>The persistence of HIV in a small pool of long-lived latently infected resting CD4+ T cells is a major barrier to viral eradication. </plain></SENT>
<SENT sid="13" pm="."><plain>Identifying cellular markers that are preferentially expressed at the surface of latently infected cells may lead to novel therapeutic strategies to cure HIV infection. </plain></SENT>
<SENT sid="14" pm="."><plain>We identified PD-1, TIGIT and LAG-3 as markers preferentially expressed at the surface of infected cells in individuals receiving ART. </plain></SENT>
<SENT sid="15" pm="."><plain>CD4+ T cells co-expressing these markers were highly enriched for cells carrying HIV. </plain></SENT>
<SENT sid="16" pm="."><plain>Our results suggest that PD-1, TIGIT and LAG-3 may represent new molecular targets to interfere with HIV persistence during ART. </plain></SENT>
</text></SecTag></p></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>1U19AI096109</award-id></award-group><award-group id="award002"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>1R21AI113096</award-id></award-group><award-group id="award003"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01AI110334</award-id></award-group><award-group id="award004"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100001117</institution-id><institution>amfAR, The Foundation for AIDS Research</institution></institution-wrap></funding-source><award-id>108687-54-RGRL</award-id><principal-award-recipient><name><surname>Chomont</surname><given-names>Nicolas</given-names></name></principal-award-recipient></award-group><award-group id="award005"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100001117</institution-id><institution>amfAR, The Foundation for AIDS Research</institution></institution-wrap></funding-source><award-id>108928-56-RGRL</award-id><principal-award-recipient><name><surname>Chomont</surname><given-names>Nicolas</given-names></name></principal-award-recipient></award-group><award-group id="award006"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100001117</institution-id><institution>amfAR, The Foundation for AIDS Research</institution></institution-wrap></funding-source><award-id>108264-51-RFRL</award-id><principal-award-recipient><name><surname>Fromentin</surname><given-names>Rémi</given-names></name></principal-award-recipient></award-group><award-group id="award007"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100000925</institution-id><institution>National Health and Medical Research Council</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Lewin</surname><given-names>Sharon R.</given-names></name></principal-award-recipient></award-group><award-group id="award008"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100000925</institution-id><institution>National Health and Medical Research Council</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Khoury</surname><given-names>Gabriela</given-names></name></principal-award-recipient></award-group><funding-statement>This work was supported by the Delaney AIDS Research Enterprise (DARE) to Find a Cure 1U19AI096109, NIH grant 1R21AI113096 (NC, SRL, SD, RPS), NIH grant R01 AI110334, the UCSF-GIVI Center for AIDS Research grant P30AI027763 and by the Foundation for AIDS Research (amfAR Research Consortium on HIV Eradication (108687-54-RGRL and 108928-56-RGRL). RF is supported by an amfAR fellowship (108264-51-RFRL). SRL is supported by a practitioner fellowship from the National Health and Medical Research Council (NHMRC) of Australia. GK is a recipient of an NHMRC Dora Lush biomedical post-graduate scholarship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="3"/><page-count count="19"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><SecTag type="INTRO"><sec sec-type="intro" id="sec001"><title><text><SENT sid="17" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="18" pm="."><plain>Although antiretroviral therapy (ART) is highly effective at suppressing HIV replication, viral reservoirs persist despite treatment and lead to rapid viral rebound when ART is interrupted [1–4]. </plain></SENT>
<SENT sid="19" pm="."><plain>A major step to achieve natural control of HIV replication after ART cessation would be to eliminate, or at least reduce, the number of long-lived infected cells from which HIV reignite infection. </plain></SENT>
<SENT sid="20" pm="."><plain>The characterization of cell surface markers that could identify HIV-infected cells persisting during ART is a research priority towards an HIV cure [5] as it could lead to the development of novel eradication strategies. </plain></SENT>
</text></p><p><text><SENT sid="21" pm="."><plain>Several subsets of CD4+ T cells harbor replication-competent HIV during ART. </plain></SENT>
<SENT sid="22" pm="."><plain>These CD4+ T cells are usually defined on the basis of their differentiation stage [6–8], functionality or homing potential [9,10]. </plain></SENT>
<SENT sid="23" pm="."><plain>Central memory (TCM) and transitional memory (TTM) CD4+ T cells were identified as the major cellular reservoirs for HIV during ART [6]. </plain></SENT>
<SENT sid="24" pm="."><plain>More recently, a less differentiated subset of long-lived cells with high self-renewal capacity, the stem-cell memory CD4+ T cells (TSCM), has been identified as a main contributor to long-term HIV persistence [7,8]. </plain></SENT>
<SENT sid="25" pm="."><plain>The functional and homing capacities of CD4+ T cells also dictate their capacity to serve as persistent reservoirs for HIV: Th17 and Th1/Th17 CD4+ T cells as well as cells expressing CCR6 and CXCR3 show increasing contribution to the viral reservoir with duration of ART [11,12]. </plain></SENT>
</text></p><p><text><SENT sid="26" pm="."><plain>Immune checkpoint molecules (ICs) are co-inhibitory receptors which down-modulate immune responses to prevent hyper-immune activation, minimize collateral damage, and maintain peripheral self-tolerance [13]. </plain></SENT>
<SENT sid="27" pm="."><plain>ICs are up regulated upon T-cell activation and constrain the effector response through feedback inhibition. </plain></SENT>
<SENT sid="28" pm="."><plain>Overexpression of these molecules is associated with T-cell exhaustion and dysfunction in cancer and chronic viral infections, including HIV [14–17]. </plain></SENT>
<SENT sid="29" pm="."><plain>We hypothesized that ICs, through their ability to inhibit T-cell activation, will favour HIV latency during ART, and that CD4+ T cells expressing ICs would be enriched for persistent HIV in individuals receiving ART. </plain></SENT>
</text></p><p><text><SENT sid="30" pm="."><plain>We focused our analysis on 7 ICs, namely PD-1 (programmed cell death-1), CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), LAG-3 (lymphocyte activation gene 3), TIGIT (T-cell immunoglobulin and ITIM domain), TIM-3 (T cell immunoglobulin and mucin 3), CD160 and 2B4 (CD244). </plain></SENT>
</text></p><p><text><SENT sid="31" pm="."><plain>PD-1, a member of the B7-CD28 superfamily, enforces an inhibitory program that blocks further TCR-induced T-cell proliferation and cytokine production [18,19]. </plain></SENT>
<SENT sid="32" pm="."><plain>In HIV infection, high levels of PD-1 are associated with T cell exhaustion [14–16,20] and incomplete immunological response to ART [21]. </plain></SENT>
<SENT sid="33" pm="."><plain>CTLA-4, a CD28 homolog, regulates the amplitude of T-cell activation by both outcompeting CD28 in binding CD80 and CD86, as well as actively delivering inhibitory signals to T cells [13]. </plain></SENT>
<SENT sid="34" pm="."><plain>TIGIT, which also belongs to the B7/CD28 superfamily, acts as a co-inhibitory molecule by directly down regulating proliferation of human T cells [22], but also by modulating cytokine secretion of DCs, decreasing IL-12 and enhancing IL-10 productions [23]. </plain></SENT>
<SENT sid="35" pm="."><plain>TIGIT has been recently associated with CD8+ T-cell dysfunction during HIV infection [24]. </plain></SENT>
<SENT sid="36" pm="."><plain>The expression of 2B4 (CD244), a member of the signalling lymphocyte activation molecule (SLAM) is also modulated on T cells during HIV infection [17,25]. </plain></SENT>
<SENT sid="37" pm="."><plain>LAG-3, a member of the immunoglobulin superfamily, is structurally highly homologous to the CD4 receptor and share MHC-II as a ligand [26]. </plain></SENT>
<SENT sid="38" pm="."><plain>Its expression on T regulatory cells plays a role in the modulation of T cell homeostasis and effector T cell responses [27,28]. </plain></SENT>
<SENT sid="39" pm="."><plain>TIM-3 is also an immunoglobulin superfamily member and its expression is increased on HIV-specific CD8+ and CD4+ T cells [29,30]. </plain></SENT>
<SENT sid="40" pm="."><plain>Finally, CD160, through its binding to its ligand Herpes Virus Entry Mediator (HVEM), an atypical member of TNF-receptor superfamily, delivers a co-inhibitory signalling to CD4+ T cells or CD8+ T cells dampening their activation in HIV-infected individuals [31,32]. </plain></SENT>
</text></p><p><text><SENT sid="41" pm="."><plain>To assess the relationship between the expression of these ICs and HIV persistence, we analysed the association between their levels of expression on CD4+ T cells and the size of the HIV reservoir in individuals receiving ART for at least 3 years. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="materials|methods" id="sec002"><title><text><SENT sid="42" pm="."><plain>Materials and Methods </plain></SENT>
</text></title><sec id="sec003"><title><text><SENT sid="43" pm="."><plain>Study participants </plain></SENT>
</text></title><p><text><SENT sid="44" pm="."><plain>Forty-eight HIV-infected participants receiving suppressive ART were recruited at the University of California San Francisco (UCSF) for this cross-sectional study. </plain></SENT>
<SENT sid="45" pm="."><plain>Participants were receiving ART for &gt;3 years, had CD4+ T-cell count &gt;350 cells/μl and HIV RNA &lt;40 copies/mL as measured by the Abbott real time HIV-1 PCR for at least 3 years. </plain></SENT>
<SENT sid="46" pm="."><plain>Whole blood (50mL) was collected by regular blood draw. </plain></SENT>
<SENT sid="47" pm="."><plain>For cell sorting experiments, 27 HIV-infected individuals were enrolled at UCSF and at VGTIFL and underwent leukapheresis. </plain></SENT>
</text></p></sec><sec id="sec004"><title><text><SENT sid="48" pm="."><plain>Ethics statement </plain></SENT>
</text></title><p><text><SENT sid="49" pm="."><plain>All subjects signed informed consent forms approved by the UCSF and Martin Memorial Health Systems review boards (IRB #10–1320, Ref # 068192 and FWA #00004139, respectively). </plain></SENT>
</text></p></sec><sec id="sec005"><title><text><SENT sid="50" pm="."><plain>Immunophenotyping </plain></SENT>
</text></title><p><text><SENT sid="51" pm="."><plain>PBMCs were isolated from peripheral blood and leukapheresis using previously described methods [6,33]. </plain></SENT>
<SENT sid="52" pm="."><plain>Cryopreserved PBMCs were thawed, washed and stained for phenotyping or cell sorting. </plain></SENT>
<SENT sid="53" pm="."><plain>Two antibody panels were used to measure the expression of IC in subsets of memory CD4+ T cells. </plain></SENT>
<SENT sid="54" pm="."><plain>The same antibody backbone was used in the two panels: CD3-Alexa700 (clone UCHT1, BD#557943), CD4-QDot605 (clone S3.5, Invitrogen#Q10008), CD8-PB (clone RPA-T8, BD#558207), CD14-V500 (clone M5E2, BD#561391), CD19-AmCyan (clone SJ25C1, BD#339190), LIVE/DEAD Aqua marker (Invitrogen#L34957), CD45RA-APC-H7 (clone HI100, BD#560674), CD27-BV650 (clone O323, Biolegend#302828) and CCR7-PE-Cy7 (clone 3D12, BD#557648). </plain></SENT>
<SENT sid="55" pm="."><plain>The following antibodies were added to this backbone: PD-1-AF647 (clone EH12.1, BD#560838), CTLA-4-PE (clone BNI3, BD#555853), LAG-3-FITC (R&amp;D#FAB2319F), TIGIT-PerCP-eF710 (clone MBSA43, eBioscience#46-9500-41), TIM-3-PE (clone F38-2E2, Biolegend#345006), CD160-AF488 (clone By55, eBioscience#53–1609), 2B4-PerCP-Cy5.5 (clone C1.7, Biolegend#329515). </plain></SENT>
<SENT sid="56" pm="."><plain>For expression of all ICs, gates were defined using fluorescence minus one controls. </plain></SENT>
<SENT sid="57" pm="."><plain>CD4+ T-cell subsets were identified by CD27, CD45RA, and CCR7 expression on CD4+ T cells after exclusion of dump positive cells (LIVE/DEAD, CD14 and CD19). </plain></SENT>
<SENT sid="58" pm="."><plain>ICs were measured in gated CD4+ T-cell subsets including naïve CD4+ T cells (CD3+CD8-CD4+CD45RA+CCR7+CD27+), central memory CD4+ T cells (CD3+CD8-CD4+CD45RA-CCR7+CD27+), transitional memory CD4+ T cells (CD3+CD8-CD4+CD45RA-CCR7-CD27+), effector memory CD4+ T cells (CD3+CD8-CD4+CD45RA-CCR7-CD27-) and terminally differentiated CD4+ T cells (CD3+CD8-CD4+CD45RA+CCR7-CD27-). </plain></SENT>
<SENT sid="59" pm="."><plain>Data was acquired on a BD LSR II flow cytometer using the FACSDiva software (Becton Dickinson) and analysed using Flow Jo version 9 (Treestar). </plain></SENT>
</text></p></sec><sec id="sec006"><title><text><SENT sid="60" pm="."><plain>Cell sorting </plain></SENT>
</text></title><p><text><SENT sid="61" pm="."><plain>Central, transitional and effector memory CD4+ T cells were sorted based on their expression of PD-1, TIGIT or LAG-3. </plain></SENT>
<SENT sid="62" pm="."><plain>The antibodies used for sorting were similar than those used for phenotyping with the exception of CD27-QDot655 (clone CLB-27/1, Invitrogen#Q10066). </plain></SENT>
<SENT sid="63" pm="."><plain>In a second set of experiments, total memory CD4+ T cells (CD3+CD4+CD45RA-) were sorted based on their expression of PD-1, TIGIT and LAG-3. </plain></SENT>
<SENT sid="64" pm="."><plain>Sorted cells were collected using an ARIA FACS sorter (Becton Dickinson). </plain></SENT>
</text></p></sec><sec id="sec007"><title><text><SENT sid="65" pm="."><plain>Isolation of total CD4+ T cells </plain></SENT>
</text></title><p><text><SENT sid="66" pm="."><plain>Total CD4+ T cells were isolated from cryopreserved PBMCs using magnetic depletion as per the manufacturer’s protocol (Stem Cell Technologies, Vancouver, Canada). </plain></SENT>
</text></p></sec><sec id="sec008"><title><text><SENT sid="67" pm="."><plain>Quantification of integrated, total and 2-LTR circles HIV DNA, cell associated unspliced HIV RNA and Tat/rev inducible multiply spliced HIV RNA </plain></SENT>
</text></title><p><text><SENT sid="68" pm="."><plain>Total CD4+ T cells or sorted CD4+ T cell subsets were used to measure the frequency of cells harboring HIV DNA (total, integrated and 2-LTR circles) by real time nested PCR as previously described [34] (S1A Text). </plain></SENT>
</text></p><p><text><SENT sid="69" pm="."><plain>The CA-US RNA was measured by real time nested PCR as previously described [35]. </plain></SENT>
<SENT sid="70" pm="."><plain>The frequency of CD4+ T cells with inducible multiply spliced HIV RNA was determined using Tat/rev inducible limiting dilution assay (TILDA) [36]. </plain></SENT>
</text></p></sec><sec id="sec009"><title><text><SENT sid="71" pm="."><plain>Statistical analysis </plain></SENT>
</text></title><p><text><SENT sid="72" pm="."><plain>Data distributions were assessed through descriptive statistics and scatter plots. </plain></SENT>
<SENT sid="73" pm="."><plain>Negative binomial regression models were run for each set of comparisons with the percentage of CD4+ T cells expressing ICs being the predictor and the measure of HIV persistence the outcome. </plain></SENT>
<SENT sid="74" pm="."><plain>We chose this approach for reasons described previously [12, 35], and for consistency with those previous publications (S1B Text). </plain></SENT>
<SENT sid="75" pm="."><plain>The approach allowed us to fit models adjusting for the effects of absolute current or nadir CD4+ T-cell, which were examined for all combinations of IC predictors and HIV persistence outcome measures. </plain></SENT>
<SENT sid="76" pm="."><plain>In addition, the negative binomial regression models take into account that copies/input is measured with less precision when the number of copies is lower and when the amount of input is lower. </plain></SENT>
<SENT sid="77" pm="."><plain>The methods also permit proper quantitative use of instances where zero copies were present in the specimen assayed, without a need for ad hoc modifications to permit taking logarithms. </plain></SENT>
<SENT sid="78" pm="."><plain>We did not evaluate the results of alternative analysis methods and did not choose the methods post-hoc based on the results that they produced. </plain></SENT>
<SENT sid="79" pm="."><plain>Analyses were run in Stata version 13.1 (Stata Corp, College Station, TX). </plain></SENT>
</text></p><p><text><SENT sid="80" pm="."><plain>For TILDA results analysis, we estimated the within-person fold difference in TILDA between the 2 cell subsets analyzed (memory CD4+ T cells expressing any versus none of the ICs) by fitting a maximum likelihood model to the raw data on numbers of positive and negative wells at each dilution (S1C Text). </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec sec-type="results" id="sec010"><title><text><SENT sid="81" pm="."><plain>Results </plain></SENT>
</text></title><sec id="sec011"><title><text><SENT sid="82" pm="."><plain>PD-1, TIGIT and LAG-3 are associated with markers of HIV persistence during ART </plain></SENT>
</text></title><p><text><SENT sid="83" pm="."><plain>To determine the relationship between ICs and HIV persistence, 48 HIV-infected participants on suppressive ART for a median time (IQR) of 8.5 years (5.0–12.4) and a median CD4+ T-cell count (IQR) of 684 cells/μL (533–858) were recruited (Table 1). </plain></SENT>
<SENT sid="84" pm="."><plain>The expressions of 7 ICs on CD4+ T cells (PD-1, CTLA-4, LAG-3, TIGIT, TIM-3, CD160 and 2B4) were measured by multiparametric flow cytometry (S1 Fig). </plain></SENT>
<SENT sid="85" pm="."><plain>The frequencies of CD4+ T cells expressing these ICs were variable (median (IQR) of 16.7% (13.2–22.7), 12.2% (8.8–16.4), 12.0% (8.9–16.1), 9.5% (3.5–18.5), 1.1% (0.8–2.5), 0.8% (0.6–1.5) and 0.7% (0.6–1.0) for TIGIT, PD-1, LAG-3, 2B4, CD160, TIM-3 and CTLA-4 respectively) (Fig 1A). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="ppat.1005761.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1005761.t001</object-id><label>Table 1</label><caption><title><text><SENT sid="86" pm="."><plain>Clinical demographics of the cohorts. </plain></SENT>
</text></title></caption><alternatives><graphic id="ppat.1005761.t001g" xlink:href="ppat.1005761.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"><text><SENT sid="87" pm="."><plain>Characteristics </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="88" pm="."><plain>Cohort 1 (N = 48) </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="89" pm="."><plain>Cohort 2 (N = 31) </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="90" pm="."><plain>Gender, n (%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="91" pm="."><plain>Male </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="92" pm="."><plain>46 (96%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="93" pm="."><plain>29 (94%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="94" pm="."><plain>Female </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="95" pm="."><plain>1 (2%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="96" pm="."><plain>2 (6%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="97" pm="."><plain>Transgender </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="98" pm="."><plain>1 (2%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="99" pm="."><plain>0 (0%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="100" pm="."><plain>Age, years median (IQR) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="101" pm="."><plain>57 (50–62) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="102" pm="."><plain>50 (50–62) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="103" pm="."><plain>Viral load, cop/mL </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="104" pm="."><plain>&lt;50 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="105" pm="."><plain>&lt;50 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="106" pm="."><plain>Nadir CD4 + T-cell count, cells/μl median (IQR) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="107" pm="."><plain>197 (110–285)a </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="108" pm="."><plain>42 (14–179)b </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="109" pm="."><plain>Current CD4 + T-cell count, cells/μl median (IQR) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="110" pm="."><plain>684 (530–862) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="111" pm="."><plain>526 (420–702) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="112" pm="."><plain>Current CD8 + T-cell count, cells/μl median (IQR) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="113" pm="."><plain>914 (639–1091) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="114" pm="."><plain>830 (617–1135) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="115" pm="."><plain>CD4/CD8 ratio median (IQR) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="116" pm="."><plain>0.77 (0.57–1.17) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="117" pm="."><plain>0.64 (0.40–0.91) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="118" pm="."><plain>ART, years median (IQR) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="119" pm="."><plain>8.5 (5.0–12.4) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="120" pm="."><plain>8.8 (6.2–12.6)c </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p><text><SENT sid="121" pm="."><plain>Data only available for (a) N = 45, (b) N = 27, (c) N = 24 </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="FIG"><fig id="ppat.1005761.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1005761.g001</object-id><label>Fig 1</label><caption><title><text><SENT sid="122" pm="."><plain>PD-1, TIGIT and LAG-3 are associated with virological markers of HIV persistence during ART. </plain></SENT>
</text></title><p><text><SENT sid="123" pm="."><plain>(A) Expression of 7 ICs on CD4+ T cells in individuals receiving suppressive ART (n = 48). </plain></SENT>
<SENT sid="124" pm="."><plain>Data is represented as percentage of CD4+ T cells and horizontal bars indicate median values with interquartile ranges. </plain></SENT>
<SENT sid="125" pm="."><plain>(B) Size of the HIV reservoir measured by integrated HIV DNA, total HIV DNA, 2-LTR circles represented as copies per million CD4+ T cells and cell-associated US HIV RNA represented as copies per million copies of 18S. </plain></SENT>
<SENT sid="126" pm="."><plain>Horizontal bars indicate median values with interquartile ranges and open circles represent the limit of detection in the negative samples (based on cell input). </plain></SENT>
<SENT sid="127" pm="."><plain>(C), (D), (E) Associations between the frequency of CD4+ T cells harboring integrated HIV DNA and the frequency of CD4+ T cells expressing PD-1, TIGIT and LAG-3, respectively. </plain></SENT>
<SENT sid="128" pm="."><plain>P values were obtained from negative binomial regression analysis. </plain></SENT>
<SENT sid="129" pm="."><plain>Effect sizes for the associations are as follows: (C) A 2-fold increase in the percentage of PD-1+ CD4+ T cell was associated with 1.43-fold increase in the frequency of CD4+ T cell harboring integrated HIV DNA, (D) a 2-fold higher percentage of TIGIT+ CD4+ T cell was associated with 1.91-fold higher integrated HIV DNA and (E) a 2-fold higher percentage of LAG-3+ CD4+ T cell was associated with 1.62-fold higher integrated HIV DNA. </plain></SENT>
<SENT sid="130" pm="."><plain>Open circles represent the limit of detection in the negative samples (based on cell input). </plain></SENT>
</text></p></caption><graphic xlink:href="ppat.1005761.g001"/></fig></SecTag><p><text><SENT sid="131" pm="."><plain>The size of the HIV reservoir was determined by measuring the frequencies of CD4+ T cells harboring integrated HIV DNA, total HIV DNA and 2-LTR circles as well as cell-associated unspliced (CA-US) HIV RNA (Fig 1B and S1 Table). </plain></SENT>
<SENT sid="132" pm="."><plain>Total HIV DNA and cell-associated US HIV RNA were detected in all samples tested, whereas integrated HIV DNA and 2-LTR circles were detected in 98%, and 80% of the samples, respectively. </plain></SENT>
</text></p><p><text><SENT sid="133" pm="."><plain>We evaluated the association between markers of HIV persistence and the frequencies of CD4+ T cells expressing ICs using a negative binomial regression model that was adjusted for current and nadir CD4+ T-cell counts when indicated (Table 2 and S2–S4 Tables). </plain></SENT>
<SENT sid="134" pm="."><plain>Using these tailored analytical methods for HIV reservoir measurements, we identified 3 ICs for which the expression on CD4+ T cells was statistically significantly associated with the frequency of CD4+ T cells harboring integrated HIV DNA, namely PD-1, TIGIT and LAG-3 (Fig 1C–1E and Table 2). </plain></SENT>
<SENT sid="135" pm="."><plain>These correlations persisted after adjusting for nadir CD4+ T-cell counts but were no longer significant after adjusting for current CD4+ T-cell count, a clinical parameter strongly associated with the size of the reservoir during ART [6,37,38]. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="ppat.1005761.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1005761.t002</object-id><label>Table 2</label><caption><title><text><SENT sid="136" pm="."><plain>Negative binomial regression models to assess the relationship between integrated HIV DNA and IC expression on CD4+ T cells. </plain></SENT>
</text></title></caption><alternatives><graphic id="ppat.1005761.t002g" xlink:href="ppat.1005761.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1"><text><SENT sid="137" pm="."><plain>Outcome </plain></SENT>
</text></th><th align="left" rowspan="2" colspan="1"><text><SENT sid="138" pm="."><plain>Predictor a  </plain></SENT>
</text></th><th align="center" colspan="2" rowspan="1"><text><SENT sid="139" pm="."><plain>Unadjusted </plain></SENT>
</text></th><th align="center" colspan="2" rowspan="1"><text><SENT sid="140" pm="."><plain>Adjusted for Current CD4 </plain></SENT>
</text></th><th align="center" colspan="2" rowspan="1"><text><SENT sid="141" pm="."><plain>Adjusted for Nadir CD4 </plain></SENT>
</text></th></tr><tr><th align="center" rowspan="1" colspan="1"><text><SENT sid="142" pm="."><plain>Result (95%CI) c  ,  d  </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="143" pm="."><plain>p-value e  </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="144" pm="."><plain>Result (95%CI) </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="145" pm="."><plain>p-value </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="146" pm="."><plain>Result (95%CI) </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="147" pm="."><plain>p-value </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="148" pm="."><plain>Integrated HIV DNA  b  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="149" pm="."><plain>PD1+ </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="150" pm="."><plain>1.43 (1.08 to 1.90) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="151" pm="."><plain>0.012 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="152" pm="."><plain>1.17 (0.91 to 1.50) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="153" pm="."><plain>0.220 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="154" pm="."><plain>1.39 (1.05 to 1.82) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="155" pm="."><plain>0.020 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="156" pm="."><plain>CTLA-4+ </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="157" pm="."><plain>1.50 (0.90 to 2.51) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="158" pm="."><plain>0.120 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="159" pm="."><plain>1.18 (0.73 to 1.91) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="160" pm="."><plain>0.500 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="161" pm="."><plain>1.43 (0.88 to 2.35) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="162" pm="."><plain>0.150 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="163" pm="."><plain>LAG-3+ </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="164" pm="."><plain>1.62 (1.07 to 2.45) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="165" pm="."><plain>0.022 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="166" pm="."><plain>1.07 (0.69 to 1.65) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="167" pm="."><plain>0.760 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="168" pm="."><plain>1.58 (1.07 to 2.35) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="169" pm="."><plain>0.023 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="170" pm="."><plain>TIGIT+ </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="171" pm="."><plain>1.91 (1.11 to 3.28) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="172" pm="."><plain>0.020 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="173" pm="."><plain>1.54 (0.91 to 2.60) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="174" pm="."><plain>0.110 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="175" pm="."><plain>1.87 (1.10 to 3.16) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="176" pm="."><plain>0.020 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="177" pm="."><plain>TIM-3+ </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="178" pm="."><plain>1.28 (0.83 to 1.97) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="179" pm="."><plain>0.260 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="180" pm="."><plain>1.24 (0.85 to 1.80) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="181" pm="."><plain>0.260 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="182" pm="."><plain>1.38 (0.89 to 2.14) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="183" pm="."><plain>0.160 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="184" pm="."><plain>CD160+ </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="185" pm="."><plain>1.07 (0.82 to 1.39) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="186" pm="."><plain>0.620 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="187" pm="."><plain>0.90 (0.69 to 1.17) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="188" pm="."><plain>0.420 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="189" pm="."><plain>1.13 (0.86 to 1.48) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="190" pm="."><plain>0.370 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="191" pm="."><plain>2B4+ </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="192" pm="."><plain>1.06 (0.83 to 1.36) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="193" pm="."><plain>0.630 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="194" pm="."><plain>0.92 (0.71 to 1.18) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="195" pm="."><plain>0.500 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="196" pm="."><plain>1.10 (0.87 to 1.39) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="197" pm="."><plain>0.440 </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p><text><SENT sid="198" pm="."><plain>a Percentage CD4+ T cells that express Immune Checkpoint Molecules </plain></SENT>
</text></p></fn><fn id="t002fn002"><p><text><SENT sid="199" pm="."><plain>b Integrated HIV DNA units (copies/million CD4+ T cells) </plain></SENT>
</text></p></fn><fn id="t002fn003"><p><text><SENT sid="200" pm="."><plain>c 95% CI = 95% confidence interval </plain></SENT>
</text></p></fn><fn id="t002fn004"><p><text><SENT sid="201" pm="."><plain>d Result interpretation: fold-change in the outcome (marker of HIV persistence) for each unit change of the predictor (Immune Checkpoint Molecules). </plain></SENT>
<SENT sid="202" pm="."><plain>All predictors were log2 transformed, so results here are interpreted as the change in the outcome for each doubling of the predictor </plain></SENT>
</text></p></fn><fn id="t002fn005"><p><text><SENT sid="203" pm="."><plain>e Statistically significant p values are &lt;0.05 and are bold </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="204" pm="."><plain>The frequency of PD-1 expressing CD4+ T cells was also associated with the frequency of CD4+ T cells harboring total HIV DNA (S3 Table), but only marginally (1.23-fold effect, p = 0.07) when the model was adjusted for current CD4+ T-cell count. </plain></SENT>
<SENT sid="205" pm="."><plain>CA-US HIV RNA and 2-LTR circles did not show statistically significant correlation with any IC expression levels, with the exception of a negative association between the frequency of CD160+ CD4+ T cells and 2-LTR circles that remained statistically significant after adjusting for current and nadir CD4+ T-cell count (S3 and S4 Tables). </plain></SENT>
</text></p></sec><sec id="sec012"><title><text><SENT sid="206" pm="."><plain>Co-expression of PD-1, TIGIT and LAG-3 is a marker of HIV persistence during ART </plain></SENT>
</text></title><p><text><SENT sid="207" pm="."><plain>ICs are co-expressed on exhausted CD4+ and CD8+ T cells during untreated HIV infection [39]. </plain></SENT>
<SENT sid="208" pm="."><plain>Using a Boolean gating strategy, we determined the frequency of CD4+ T cells co-expressing PD-1 and/or TIGIT and/or LAG-3 in our cohort of 48 HIV-infected participants receiving suppressive ART (Fig 2A and 2B). </plain></SENT>
<SENT sid="209" pm="."><plain>The majority of CD4+ T cells did not express any of these markers (median (IQR) of 65.8% (59.0–72.4)) (S6 Table). </plain></SENT>
<SENT sid="210" pm="."><plain>Less than 10% (8.5%) of CD4+ T cells expressed more than one of these markers and 0.9% simultaneously expressed PD-1, TIGIT and LAG-3. </plain></SENT>
<SENT sid="211" pm="."><plain>We further assessed if the frequency of these discrete CD4+ T-cell subsets was associated with markers of HIV persistence. </plain></SENT>
<SENT sid="212" pm="."><plain>Using the negative binomial regression model, we found that the frequency of CD4+ T cells not expressing PD-1, TIGIT and LAG-3 was strongly and negatively correlated to the frequency of CD4+ T cells harboring integrated HIV DNA (p = 0.002, Table 3 and Fig 2C). </plain></SENT>
<SENT sid="213" pm="."><plain>Conversely, the frequency of CD4+ T cell co-expressing PD-1, TIGIT and LAG-3 was strongly and positively associated with the frequency of CD4+ T cells harboring integrated HIV DNA (p = 0.001, Table 3 and Fig 2F). </plain></SENT>
<SENT sid="214" pm="."><plain>Interestingly, the frequencies of CD4+ T cells co-expressing TIGIT with either PD-1 or LAG-3 were also positively associated with the frequency of CD4+ T cells harboring integrated HIV DNA (p = 0.002 and p = 0.029 respectively, Table 3 and Fig 2D and 2E). </plain></SENT>
<SENT sid="215" pm="."><plain>Although several of these associations were less or no longer statistically significant when the model was adjusted for the current CD4+ T-cell count, the association between the size of the HIV reservoir and the frequency of triple positive cells (PD-1+, LAG-3+ and TIGIT+) remained statistically significant after adjustment (p = 0.038). </plain></SENT>
<SENT sid="216" pm="."><plain>Adjusting for duration of ART did not produce any substantial changes to the results from the unadjusted analysis (all fold-effects adjusted for ART duration within 7% of those unadjusted). </plain></SENT>
<SENT sid="217" pm="."><plain>All together, these results indicate that the co-expression of PD-1, TIGIT and LAG-3 identifies a unique subset of CD4+ T cells that strongly predicts the frequency of cells harboring integrated HIV DNA during ART. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="ppat.1005761.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1005761.g002</object-id><label>Fig 2</label><caption><title><text><SENT sid="218" pm="."><plain>Co-expression of PD-1, TIGIT and LAG-3 is a marker of HIV persistence during ART. </plain></SENT>
</text></title><p><text><SENT sid="219" pm="."><plain>(A) Frequency of CD4+ T cells co-expressing PD-1 and/or TIGIT and/or LAG-3 (PD-1/TIGIT/LAG-3 triple–(P-T-L-), PD-1 single + (P+), TIGIT single + (T+), LAG-3 single + (L+), PD-1/TIGIT double + (P+T+), TIGIT/LAG-3 double + (T+L+), PD-1/LAG-3 double + (P+L+) and PD-1/TIGIT/LAG-3 triple + (P+T+L+)) determined by Boolean gating in cohort 1 (n = 48). </plain></SENT>
<SENT sid="220" pm="."><plain>Horizontal bars indicate median values with interquartile ranges. </plain></SENT>
<SENT sid="221" pm="."><plain>(B) Venn diagram showing the pattern of co-expression of PD-1, TIGIT and LAG-3. </plain></SENT>
<SENT sid="222" pm="."><plain>(C), (D), (E), (F) Associations between the frequency of CD4+ T cells harboring integrated HIV DNA and the frequency of CD4+ T cells expressing none of these markers (triple–), PD-1 and TIGIT (double +), TIGIT and LAG-3 (double +) and PD-1 and TIGIT and LAG-3 (triple +), respectively. </plain></SENT>
<SENT sid="223" pm="."><plain>P values were obtained from negative binomial regression analysis. </plain></SENT>
<SENT sid="224" pm="."><plain>Effect sizes for the associations are as follows: (C) 0.69-fold-change in integrated HIV DNA for 1 point increase in percentage of PD-1/TIGIT/LAG-3 triple—CD4+ T cells, (D) 1.18-fold-change in integrated HIV DNA for 1 point increase in percentage of PD-1/TIGIT double + CD4+ T cells, (E) 1.30-fold-change in integrated HIV DNA for 1 point increase in percentage of TIGIT/LAG-3 double + CD4+ T cells and (F) 1.94-fold-change in integrated HIV DNA for 1 point increase in percentage of PD-1/TIGIT/LAG-3 triple + CD4+ T cells. </plain></SENT>
<SENT sid="225" pm="."><plain>Open circles represent the limit of detection in the negative samples (based on cell input). </plain></SENT>
</text></p></caption><graphic xlink:href="ppat.1005761.g002"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="ppat.1005761.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1005761.t003</object-id><label>Table 3</label><caption><title><text><SENT sid="226" pm="."><plain>Negative binomial regression models to assess the relationship between Integrated HIV DNA and the frequency of CD4+ T cells expressing PD-1 and/or TIGIT and/or LAG-3. </plain></SENT>
</text></title></caption><alternatives><graphic id="ppat.1005761.t003g" xlink:href="ppat.1005761.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1"><text><SENT sid="227" pm="."><plain>Outcome </plain></SENT>
</text></th><th align="left" rowspan="2" colspan="1"><text><SENT sid="228" pm="."><plain>Predictor a  </plain></SENT>
</text></th><th align="center" colspan="2" rowspan="1"><text><SENT sid="229" pm="."><plain>Unadjusted </plain></SENT>
</text></th><th align="center" colspan="2" rowspan="1"><text><SENT sid="230" pm="."><plain>Adjusted for Current CD4 </plain></SENT>
</text></th><th align="center" colspan="2" rowspan="1"><text><SENT sid="231" pm="."><plain>Adjusted for Nadir CD4 </plain></SENT>
</text></th><th align="center" colspan="2" rowspan="1"><text><SENT sid="232" pm="."><plain>Adjusted for ART duration </plain></SENT>
</text></th></tr><tr><th align="center" rowspan="1" colspan="1"><text><SENT sid="233" pm="."><plain>Result (95%CI)  c  ,  d  </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="234" pm="."><plain>p-value e  </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="235" pm="."><plain>Result (95%CI) </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="236" pm="."><plain>p-value </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="237" pm="."><plain>Result (95%CI) </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="238" pm="."><plain>p-value </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="239" pm="."><plain>Result (95%CI) </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="240" pm="."><plain>p-value </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="8" colspan="1"><text><SENT sid="241" pm="."><plain>Integrated HIV DNA b  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="242" pm="."><plain>PD-1/TIGIT/LAG-3 triple – f  </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="243" pm="."><plain>0.69 (0.54 to 0.87) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="244" pm="."><plain>0.002 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="245" pm="."><plain>0.82 (0.65 to 1.03) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="246" pm="."><plain>0.084 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="247" pm="."><plain>0.70 (0.56 to 0.86) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="248" pm="."><plain>0.001 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="249" pm="."><plain>0.68 (0.54–0.85) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="250" pm="."><plain>0.001 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="251" pm="."><plain>PD-1 single + f  </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="252" pm="."><plain>1.24 (0.90 to 1.70) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="253" pm="."><plain>0.187 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="254" pm="."><plain>1.09 (0.80 to 1.48) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="255" pm="."><plain>0.578 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="256" pm="."><plain>1.28 (0.94 to 1.75) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="257" pm="."><plain>0.118 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="258" pm="."><plain>1.32 (0.93–1.88) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="259" pm="."><plain>0.12 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="260" pm="."><plain>TIGIT single + </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="261" pm="."><plain>1.06 (0.99 to 1.14) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="262" pm="."><plain>0.106 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="263" pm="."><plain>1.05 (0.98 to 1.12) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="264" pm="."><plain>0.210 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="265" pm="."><plain>1.06 (0.99 to 1.13) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="266" pm="."><plain>0.111 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="267" pm="."><plain>1.06 (0.98–1.14) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="268" pm="."><plain>0.13 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="269" pm="."><plain>LAG-3 single + </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="270" pm="."><plain>1.00 (0.95 to 1.05) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="271" pm="."><plain>0.963 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="272" pm="."><plain>0.97 (0.92 to 1.02) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="273" pm="."><plain>0.176 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="274" pm="."><plain>1.00 (0.94 to 1.05) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="275" pm="."><plain>0.848 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="276" pm="."><plain>1.00 (0.95–1.05) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="277" pm="."><plain>0.86 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="278" pm="."><plain>PD-1/TIGIT double + </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="279" pm="."><plain>1.18 (1.07 to 1.31) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="280" pm="."><plain>0.002 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="281" pm="."><plain>1.13 (1.00 to 1.26) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="282" pm="."><plain>0.042 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="283" pm="."><plain>1.17 (1.06 to 1.30) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="284" pm="."><plain>0.003 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="285" pm="."><plain>1.19 (1.07–1.32) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="286" pm="."><plain>0.001 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="287" pm="."><plain>TIGIT/LAG-3 double + </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="288" pm="."><plain>1.30 (1.03 to 1.64) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="289" pm="."><plain>0.029 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="290" pm="."><plain>1.16 (0.97 to 1.38) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="291" pm="."><plain>0.100 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="292" pm="."><plain>1.27 (1.04 to 1.55) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="293" pm="."><plain>0.018 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="294" pm="."><plain>1.29 (1.02–1.65) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="295" pm="."><plain>0.037 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="296" pm="."><plain>LAG-3/PD-1 double + </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="297" pm="."><plain>1.08 (0.96 to 1.23) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="298" pm="."><plain>0.206 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="299" pm="."><plain>1.01 (0.88 to 1.16) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="300" pm="."><plain>0.910 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="301" pm="."><plain>1.09 (0.96 to 1.25) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="302" pm="."><plain>0.175 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="303" pm="."><plain>1.11 (0.96–1.23) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="304" pm="."><plain>0.15 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="305" pm="."><plain>PD-1/TIGIT/LAG-3 triple + </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="306" pm="."><plain>1.94 (1.33 to 2.83) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="307" pm="."><plain>0.001 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="308" pm="."><plain>1.45 (1.02 to 2.05) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="309" pm="."><plain>0.038 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="310" pm="."><plain>1.86 (1.26 to 2.72) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="311" pm="."><plain>0.002 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="312" pm="."><plain>1.92 (1.31–2.81) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="313" pm="."><plain>0.001 </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p><text><SENT sid="314" pm="."><plain>a Percentage CD4+ T cells that express Immune Checkpoint Molecules </plain></SENT>
</text></p></fn><fn id="t003fn002"><p><text><SENT sid="315" pm="."><plain>b Integrated HIV DNA units (copies/million CD4+ T cells) </plain></SENT>
</text></p></fn><fn id="t003fn003"><p><text><SENT sid="316" pm="."><plain>c 95% CI = 95% confidence interval </plain></SENT>
</text></p></fn><fn id="t003fn004"><p><text><SENT sid="317" pm="."><plain>d Result interpretation: fold-change in the outcome (marker of HIV persistence) for each one point increase in the percent of cells expressing the predictor (PD-1 and/or TIGIT and/or LAG-3) </plain></SENT>
</text></p></fn><fn id="t003fn005"><p><text><SENT sid="318" pm="."><plain>e Statistically significant p values are &lt;0.05 and are bold </plain></SENT>
</text></p></fn><fn id="t003fn006"><p><text><SENT sid="319" pm="."><plain>f These predictors vary more than others, so results are scaled to be per 10 point increase in percent of cells, rather than per one point increase </plain></SENT>
</text></p></fn><fn id="t003fn007"><p><text><SENT sid="320" pm="."><plain>When the negative binomial regression model was used to assess the relationship between Total HIV DNA, 2-LTR circles, CA-US RNA and the frequency of CD4+ T cells expressing PD-1 and/or TIGIT and/or LAG-3, no association show statistically significant, with the exception of the frequency of CD4+ T cells harboring total HIV DNA and the frequency of PD-1 single + (p = 0.005, 1.10-fold-change in total HIV DNA for 1 point increase in percentage of PD-1 single + CD4+ T cells) and PD-1/TIGIT double + CD4+ T cells (p = 0.017, 1.40-fold-change in total HIV DNA for 1 point increase in percentage of PD-1/TIGIT double + CD4+ T cells). </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag></sec><sec id="sec013"><title><text><SENT sid="321" pm="."><plain>Expressions of PD-1, TIGIT and LAG-3 are associated with HIV-infected cells in distinct memory CD4+ T-cell subsets during ART </plain></SENT>
</text></title><p><text><SENT sid="322" pm="."><plain>HIV persists preferentially in memory CD4+ T-cell subsets [6–8]. </plain></SENT>
<SENT sid="323" pm="."><plain>To determine the role played by ICs in each individual CD4+ T-cell memory subset, we first analyzed the expression of PD-1, TIGIT and LAG-3, the 3 ICs we identified to be associated with HIV persistence, on naïve (TN), central memory (TCM), transitional memory (TTM), effector memory (TEM) and terminally differentiated (TTD) cells in 48 HIV-infected participants (Cohort 1: clinical characteristics in Table 1) (Fig 3A, 3B and 3C respectively). </plain></SENT>
<SENT sid="324" pm="."><plain>As expected, TN cells expressed low levels of these ICs. </plain></SENT>
<SENT sid="325" pm="."><plain>The frequency of CD4+ T cells expressing PD-1 or LAG-3 increased with differentiation, with TEM cells displaying the highest levels of expression of these markers. </plain></SENT>
<SENT sid="326" pm="."><plain>The highest frequency of TIGIT+ cells was found within the TTM subset. </plain></SENT>
<SENT sid="327" pm="."><plain>These results demonstrated that the subsets of memory cells that were previously shown to harbor persistent HIV during ART express PD-1, TIGIT and LAG-3. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="ppat.1005761.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1005761.g003</object-id><label>Fig 3</label><caption><title><text><SENT sid="328" pm="."><plain>PD-1, TIGIT and LAG-3 identify HIV-infected cells in distinct memory CD4+ T-cell subsets during ART. </plain></SENT>
</text></title><p><text><SENT sid="329" pm="."><plain>(A), (B), (C) Frequencies of memory CD4+ T-cell subsets (naïve (TN), central memory (TCM), transitional memory (TTM), effector memory (TEM) and terminally differentiated (TD)) expressing PD-1, TIGIT or LAG-3, respectively. </plain></SENT>
<SENT sid="330" pm="."><plain>Horizontal bars indicate median values with interquartile ranges. </plain></SENT>
<SENT sid="331" pm="."><plain>(D), (E), (F) Frequencies of cells harboring integrated HIV DNA in TCM, TTM and TEM CD4+ T-cell subsets sorted based on their expression of PD-1 (n = 12), TIGIT (n = 9) or LAG-3 (n = 7), respectively. </plain></SENT>
<SENT sid="332" pm="."><plain>Results are expressed as the HIV copy number in million cells of a given subset. </plain></SENT>
<SENT sid="333" pm="."><plain>P values were obtained from negative binomial regression analysis. </plain></SENT>
<SENT sid="334" pm="."><plain>Significant differences (p&lt;0.05) are designated by a p value in bold. </plain></SENT>
<SENT sid="335" pm="."><plain>Open circles represent the limit of detection in the negative samples (based on cell input). </plain></SENT>
</text></p></caption><graphic xlink:href="ppat.1005761.g003"/></fig></SecTag><p><text><SENT sid="336" pm="."><plain>To determine whether PD-1, TIGIT and LAG-3 identify cells more likely to carry persistent HIV in virally suppressed participants, individual memory CD4+ T-cell subsets were sorted based on their expression of PD-1, TIGIT or LAG-3 in a subset of subjects who underwent leukapheresis (Cohort 2: clinical characteristics in Table 1) and the results were analyzed by negative binomial regression model (S5 Table). </plain></SENT>
<SENT sid="337" pm="."><plain>The frequency of cells harboring integrated HIV DNA was moderately higher in PD-1 expressing TTM when compared to their PD-1 negative counterparts (p = 0.053, fold-difference = 1.5) (Fig 3D). </plain></SENT>
<SENT sid="338" pm="."><plain>TEM cells expressing TIGIT were enriched for integrated genomes when compared to their TIGIT- counterparts (p = 0.001, fold-difference = 2.7) (Fig 3E). </plain></SENT>
<SENT sid="339" pm="."><plain>Finally, all the memory CD4+ T-cell subsets (TCM, TTM and TEM cells) expressing LAG-3 were enriched for integrated HIV DNA when compared to their negative counterparts (p&lt;0.0001, fold-difference = 1.9, p = 0.003, fold-difference = 1.8 and p = 0.030, fold-difference = 2.5 respectively) (Fig 3F). </plain></SENT>
<SENT sid="340" pm="."><plain>All together these results indicate that PD-1, TIGIT and LAG-3 enrich for infected cells in distinct memory CD4+ T-cell subsets in individuals on ART. </plain></SENT>
<SENT sid="341" pm="."><plain>We calculated the contribution of cells expressing PD-1, TIGIT or LAG-3 to the total reservoir by taking into account the frequency of these subsets within the CD4 compartment and their relative infection frequencies. </plain></SENT>
<SENT sid="342" pm="."><plain>The mean contributions of CD4+ T cells expressing PD-1, TIGIT and LAG-3 were 29%, 34% and 31%, respectively (S2 Fig). </plain></SENT>
<SENT sid="343" pm="."><plain>As a comparator, TCM, TTM and TEM cells contributed 43%, 27% and 24% to the pool of infected cells in these same virally suppressed individuals. </plain></SENT>
<SENT sid="344" pm="."><plain>These data indicate that a third of the reservoir is encompassed in cells expressing each individual marker. </plain></SENT>
</text></p></sec><sec id="sec014"><title><text><SENT sid="345" pm="."><plain>Co-expression of PD-1, TIGIT and LAG-3 highly enriches in HIV-infected memory CD4+ T cells during ART </plain></SENT>
</text></title><p><text><SENT sid="346" pm="."><plain>We then determined if the combination of PD-1, TIGIT and LAG-3 would further enrich memory CD4+ T cells for HIV-infected cells during ART. </plain></SENT>
<SENT sid="347" pm="."><plain>The average frequency of cells expressing 0, 1, 2 or 3 of these markers in the memory CD4+ T compartment (CD45RA-) from our cohort of 48 individuals (Table 1) indicated that an average of 33% of memory CD4+ T cells expressed one of the 3 IC only, 12% expressed 2 and 2% expressed the 3 markers simultaneously. </plain></SENT>
<SENT sid="348" pm="."><plain>Large numbers of memory CD4+ T cells were sorted based on their expression of PD-1, TIGIT and LAG-3 from 5 individuals. </plain></SENT>
<SENT sid="349" pm="."><plain>The combination of these 3 markers allowed us to sort eight subsets of cells to high purity, namely PD-1/TIGIT/LAG-3 triple -, PD-1 single +, TIGIT single +, LAG-3 single +, PD-1/TIGIT double +, TIGIT/LAG-3 double +, PD-1/LAG-3 double + and PD-1/TIGIT/LAG-3 triple + cells. </plain></SENT>
<SENT sid="350" pm="."><plain>The frequency of cells harboring integrated HIV DNA was measured by qPCR in each sorted subset (S3 Fig) and the mean frequency for each category was calculated relative to total CD4+ T cells (Fig 4B). </plain></SENT>
<SENT sid="351" pm="."><plain>Memory CD4+ T cells showed a gradual enrichment in HIV-infected cells when expressing an increasing number of ICs. </plain></SENT>
<SENT sid="352" pm="."><plain>Memory CD4+ T cells expressing simultaneously PD-1, TIGIT and LAG-3 were enriched for HIV-infected cells up to 10 times more when compared to total CD4+ T cells, with a median fold increase (IQR) of 8.15 (4.92–9.59). </plain></SENT>
<SENT sid="353" pm="."><plain>These results demonstrated that memory CD4+ T cells expressing a combination of ICs were highly enriched for integrated HIV DNA during ART. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="ppat.1005761.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1005761.g004</object-id><label>Fig 4</label><caption><title><text><SENT sid="354" pm="."><plain>Co-expression of PD-1, TIGIT and LAG-3 identifies HIV-infected cells during ART. </plain></SENT>
</text></title><p><text><SENT sid="355" pm="."><plain>(A) Pie chart representing the frequencies of memory CD4+ T cells co-expressing PD-1 and/or TIGIT and/or LAG-3 in cohort 1 (n = 48). </plain></SENT>
<SENT sid="356" pm="."><plain>Coloured bars on the right side designate categories of ICs expressing cells: Triple -: PD-1/TIGIT/LAG-3 triple—in blue; single +: PD-1 single +, TIGIT single +, LAG-3 single + in green; double +: PD-1/TIGIT double +, TIGIT/LAG-3 double +, PD-1/LAG-3 double + in orange and triple +: PD-1/TIGIT/LAG-3 triple + in red. </plain></SENT>
<SENT sid="357" pm="."><plain>(B) Frequency of memory CD4+ T cells harboring integrated HIV DNA represented as a fold change over frequency in total CD4+ T cells. </plain></SENT>
<SENT sid="358" pm="."><plain>Mean values and standard deviations from 5 independent donors are represented (n = 5). </plain></SENT>
<SENT sid="359" pm="."><plain>(C) Frequency of cells harboring inducible msRNA measured by TILDA in memory CD4+ T cells expressing any (i.e. at least one) versus none of PD-1, TIGIT or LAG-3 (mLPT+ and mLPT- respectively). </plain></SENT>
<SENT sid="360" pm="."><plain>P value and fold-difference were obtained from a maximum likelihood model. </plain></SENT>
</text></p></caption><graphic xlink:href="ppat.1005761.g004"/></fig></SecTag><p><text><SENT sid="361" pm="."><plain>As the majority of HIV genomes, even when integrated, are defective [40], we assessed if PD-1, TIGIT and LAG-3 identify cells in which HIV production can be induced. </plain></SENT>
<SENT sid="362" pm="."><plain>As the frequency of triple positive cells was too low to perform this experiment, we sorted memory CD4+ T cells (CD45RA-) expressing any (i.e. at least one) versus none of PD-1, TIGIT or LAG-3 (mLPT+ and mLPT- respectively). </plain></SENT>
<SENT sid="363" pm="."><plain>We measured the frequency of cells in each population that transcribe multiply spliced HIV RNA molecules upon induction with PMA/ionomycin using the Tat/rev induced limiting dilution assay (TILDA) [36]. </plain></SENT>
<SENT sid="364" pm="."><plain>Tat/rev transcripts were detectable by TILDA in both cell subsets from all of the 8 individuals tested. </plain></SENT>
<SENT sid="365" pm="."><plain>The rate of inducible virus per million cells was estimated in our maximum likelihood model to average 3.0-fold higher in mLPT+ cells than in mLPT- cells from the same participant (95% CI 1.0 to 9.0, p = 0.049, S1C Text) (Fig 4C). </plain></SENT>
<SENT sid="366" pm="."><plain>Taking into account the frequency of these cell subsets, the contribution of cells expressing at least one of these markers to the total pool of memory CD4+ T cells infected with inducible HIV genomes was calculated. </plain></SENT>
<SENT sid="367" pm="."><plain>This contribution ranged from 30 to 98% (median of 76%), indicating that the majority of inducible HIV genomes were found in memory CD4+ T cells expressing at least one of these markers. </plain></SENT>
<SENT sid="368" pm="."><plain>These experiments provide evidence that memory CD4+ T cells expressing PD-1, TIGIT and/or LAG-3 are enriched for HIV-infected CD4+ T cells harboring inducible proviruses during ART. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="conclusions" id="sec015"><title><text><SENT sid="369" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="370" pm="."><plain>In this study, we identified PD-1, TIGIT and LAG-3 as novel markers of cells that are more frequently infected in HIV-infected individuals receiving suppressive ART. </plain></SENT>
<SENT sid="371" pm="."><plain>Co-expression of the 3 ICs identified a unique subset of CD4+ T cells that was strongly associated with the size of the HIV reservoir and that was highly enriched for integrated HIV DNA. </plain></SENT>
<SENT sid="372" pm="."><plain>Finally, our results provide evidence that memory CD4+ T cells expressing at least one of these markers are the major contributors to the pool of inducible HIV genomes during ART. </plain></SENT>
</text></p><p><text><SENT sid="373" pm="."><plain>The frequencies of CD4+ T cells expressing PD-1, CTLA-4, LAG-3 and TIM-3 were similar to those reported by other groups [41–44], indicating that the cohort of participants used for this study is likely to be representative of the HIV population receiving suppressive ART. </plain></SENT>
<SENT sid="374" pm="."><plain>In addition, the association between PD-1 and TIGIT expression on CD4+ T cells and the frequency of CD4+ T cells carrying HIV proviruses was in agreement with previously reported findings [6,24,41]. </plain></SENT>
</text></p><p><text><SENT sid="375" pm="."><plain>We found positive associations between the expression of PD-1, LAG-3 and TIGIT in CD4+ T cells and the frequency of cells harboring integrated HIV DNA. </plain></SENT>
<SENT sid="376" pm="."><plain>Of note, these three markers showed the strongest inverse associations with CD4+ T cell counts among the 7 markers we examined, suggesting a link between T cell homeostasis and HIV persistence (S4A, S4B and S4C Fig). </plain></SENT>
<SENT sid="377" pm="."><plain>The associations between individual IC expression and HIV persistence marker were substantially smaller and no longer statistically significant after adjusting for current CD4+ T-cell count. </plain></SENT>
<SENT sid="378" pm="."><plain>These findings from the negative binomial regression models suggest that the current CD4+ T-cell count is an important predictor of the size of the HIV reservoir when measured as the frequency of cells harboring proviral genomes [6,37]. </plain></SENT>
<SENT sid="379" pm="."><plain>Importantly, and in contrast to cells expressing a single marker, the frequency of cells co-expressing simultaneously PD-1, TIGIT and LAG-3 was strongly associated with the size of the reservoir and remained after adjusting for nadir and current CD4+ T-cell counts. </plain></SENT>
<SENT sid="380" pm="."><plain>This result reinforces the possibility of a direct—and maybe synergistic—role for these molecules in HIV persistence during ART. </plain></SENT>
<SENT sid="381" pm="."><plain>In addition, the frequency of CD4+ T cells co-expressing simultaneously PD-1, TIGIT and LAG-3 positively correlated with the frequency of CD4+ T cells expressing HLADR/CD38 (p = 0.003, r = 0.42) and Ki67 (p = 0.022, r = 0.33) (S1D and S1E Text and S4D and S4E Fig). </plain></SENT>
<SENT sid="382" pm="."><plain>These associations suggest that the persistence of the small pool of cells expressing the 3 markers is associated with T cell activation and proliferation. </plain></SENT>
</text></p><p><text><SENT sid="383" pm="."><plain>Interestingly, we observed a strong negative association between CD160 expression and 2-LTR circles. </plain></SENT>
<SENT sid="384" pm="."><plain>Notably, this correlation remained after adjusting for current and nadir CD4+ T cell counts. </plain></SENT>
<SENT sid="385" pm="."><plain>A possible explanation for these findings is that CD160+ cells may be preferential targets for infection and depletion during ART, which would explain the strong negative association between the frequency of CD160+ CD4+ T cells and a putative marker of persistent viral replication. </plain></SENT>
</text></p><p><text><SENT sid="386" pm="."><plain>By sorting TCM, TTM and TEM cells expressing PD-1, TIGIT and LAG-3, we observed that cells expressing these markers were enriched for HIV-infected cells in different memory CD4+ T-cells subsets during ART. </plain></SENT>
<SENT sid="387" pm="."><plain>While LAG-3 enriched for integrated HIV DNA in all memory subsets (TCM, TTM, and TEM), PD-1 and TIGIT enriched for HIV genomes exclusively in TTM and TEM cells, respectively. </plain></SENT>
<SENT sid="388" pm="."><plain>These observations suggest that ICs may exert different pro-latency effects in subsets endowed with distinct proliferative and activation status. </plain></SENT>
<SENT sid="389" pm="."><plain>One may hypothesize that different ICs provide infected cells with different selective advantage to persist by counteracting distinct stimuli specific to an individual memory cell subset. </plain></SENT>
<SENT sid="390" pm="."><plain>Further investigations will be needed to characterize the mechanisms by which these ICs may specifically contribute to HIV persistence within these distinct subsets. </plain></SENT>
</text></p><p><text><SENT sid="391" pm="."><plain>Overall, the majority of inducible HIV genomes were found in memory CD4+ T cells expressing at least one of these markers (median of 76%). </plain></SENT>
<SENT sid="392" pm="."><plain>Although triple negative cells also contain inducible HIV genomes, our data provide evidence that there is an enrichment for inducible viral genomes in CD4+ T cells expressing these markers. </plain></SENT>
</text></p><p><text><SENT sid="393" pm="."><plain>Importantly, we found a gradual enrichment in integrated HIV DNA in cells that express multiple ICs simultaneously. </plain></SENT>
<SENT sid="394" pm="."><plain>This observation mirrors the synergistic mechanisms of action of these receptors to dampen T cell functions. </plain></SENT>
<SENT sid="395" pm="."><plain>Indeed, LAG-3 and PD-1 are commonly co-expressed on exhausted or dysfunctional T cells in models of chronic infections [45], autoimmune diseases [46], and cancers [47,48]. </plain></SENT>
<SENT sid="396" pm="."><plain>Potential synergistic functions were highlighted in murine models of autoimmune diseases [49]. </plain></SENT>
<SENT sid="397" pm="."><plain>Anti-LAG-3 blocking mAb has recently entered clinical testing in cancer in monotherapy or in combination therapy with anti-PD-1 (NCT01968109). </plain></SENT>
<SENT sid="398" pm="."><plain>Additionally, TIGIT is co-expressed with PD-1 on activated CD8+ tumor-infiltrating lymphocytes from patients with melanoma [50]. </plain></SENT>
<SENT sid="399" pm="."><plain>Blockages of TIGIT and PD-1 synergize to improve T cell proliferation, cytokines production and degranulation in vivo in melanoma treatment and in vitro in HIV infection [24,50]. </plain></SENT>
<SENT sid="400" pm="."><plain>All together, these studies indicate that ICs can synergize to repress T cell functions and suggest that these synergies may also play a role in HIV persistence during ART. </plain></SENT>
</text></p><p><text><SENT sid="401" pm="."><plain>The expression of PD-1, LAG-3 and TIM-3 on CD4+ and CD8+ T cells prior to ART was recently identified as a strong predictor of time to viral rebound after treatment interruption in the SPARTAC study [43]. </plain></SENT>
<SENT sid="402" pm="."><plain>It is possible that CD4+ T cells expressing these markers before ART represent a preferential niche for the establishment of a stable reservoir for HIV and that latently infected cells expressing these markers preferentially persist during ART, as suggested by our observations. </plain></SENT>
<SENT sid="403" pm="."><plain>In our study, we identified a discrete subset of CD4+ T cells co-expressing PD-1, TIGIT and LAG-3 as an important predictor of the frequency of cells harboring integrated HIV DNA during ART. </plain></SENT>
<SENT sid="404" pm="."><plain>Of note, the expression of TIGIT before ART initiation was not measured in the SPARTAC study and further studies will be needed to determine if this IC could also represent a pre-ART predictor of viral rebound. </plain></SENT>
</text></p><p><text><SENT sid="405" pm="."><plain>Our data provide a rationale for the use of immune checkpoint blockers (ICBs) to target latently infected cells during ART. </plain></SENT>
<SENT sid="406" pm="."><plain>Targeting ICs by ICBs, a novel class of molecules in development in oncology, may have a double benefit in the context of HIV remission by both targeting latently infected cells and restoring HIV-specific T cell immunity. </plain></SENT>
<SENT sid="407" pm="."><plain>By enhancing T cell activation and increasing viral transcription, ICBs may facilitate HIV reactivation in latently infected cells when used alone or in combination with latency reversing agents. </plain></SENT>
<SENT sid="408" pm="."><plain>The anti-CTLA-4 antibody iplimumab was recently shown to significantly increase CA-US HIV RNA in an HIV-infected individual on ART, consistent with latency reversal [51]. </plain></SENT>
<SENT sid="409" pm="."><plain>An alternative mechanism of action of some ICBs would be to directly deplete cells expressing these markers, as observed with the anti-CTLA-4 ipilumimab, which induces direct elimination of CTLA-4+ regulatory T cells in tumor tissue in patients with melanoma [52]. </plain></SENT>
<SENT sid="410" pm="."><plain>Our results suggest that the administration of antibodies with effector functions targeting PD-1, LAG-3 and TIGIT may significantly reduce the size of the latent HIV reservoir during ART by targeting cells in which HIV persists. </plain></SENT>
</text></p><p><text><SENT sid="411" pm="."><plain>Several limitations are associated with our study. </plain></SENT>
<SENT sid="412" pm="."><plain>We have not adjusted p-values for multiple comparisons, because such adjustment would neglect the biological relationships among our positive results and would require that each analysis detract from the others, rather than reinforcing one another when there is biological coherence [53] (S1F Text). </plain></SENT>
<SENT sid="413" pm="."><plain>Nevertheless, our evidence may be weaker than if it had arisen from a narrower set of analyses, and, in any case, additional studies will be needed to confirm the hypotheses supported by our results. </plain></SENT>
<SENT sid="414" pm="."><plain>Most of our analyses were performed using integrated HIV DNA as a marker of HIV persistence. </plain></SENT>
<SENT sid="415" pm="."><plain>We chose this readout as it was applicable to small subsets of CD4+ T cells on which measures of replication competent HIV cannot be performed. </plain></SENT>
<SENT sid="416" pm="."><plain>The majority of viral genomes persisting during ART are known to be defective [40,54], and although our experiments indicate that cells that express ICs can produce multiply spliced RNA upon activation (TILDA), they do not demonstrate that replication competent virus persists in these cells. </plain></SENT>
<SENT sid="417" pm="."><plain>In addition, our results are limited to circulating T cells. </plain></SENT>
<SENT sid="418" pm="."><plain>It is possible and indeed likely that the biology of ICs expression and HIV persistence will differ in tissues, particularly in secondary lymphoid tissues where many of the ligands for these receptors are likely to be expressed. </plain></SENT>
</text></p><p><text><SENT sid="419" pm="."><plain>A better understanding of the nature of the cells that encompass the latent HIV reservoir is a prerequisite to the development of novel curative strategies. </plain></SENT>
<SENT sid="420" pm="."><plain>Despite similarities in their mechanisms of action, PD-1, TIGIT and LAG-3 are likely to be non-redundant in their functions. </plain></SENT>
<SENT sid="421" pm="."><plain>Blocking these pathways simultaneously may show synergies in latency reversal, as suggested by their synergistic activities in the restoration of T cell immunity. </plain></SENT>
</text></p></sec></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material" id="sec016"><title><text><SENT sid="422" pm="."><plain>Supporting Information </plain></SENT>
</text></title><supplementary-material content-type="local-data" id="ppat.1005761.s001"><label>S1 Text</label><caption><title><text><SENT sid="423" pm="."><plain>Materials &amp; Methods supporting information. </plain></SENT>
</text></title><p><text><SENT sid="424" pm="."><plain>(DOCX) </plain></SENT>
</text></p></caption><media xlink:href="ppat.1005761.s001.docx"><caption><p><text><SENT sid="425" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1005761.s002"><label>S1 Fig</label><caption><title><text><SENT sid="426" pm="."><plain>Gating strategy of 7 ICs on CD4+ T cells. </plain></SENT>
</text></title><p><text><SENT sid="427" pm="."><plain>Expression of PD-1, CTLA-4, LAG-3, TIGIT, TIM-3, CD160 and 2B4 on CD4+ T cells in individuals receiving suppressive ART (n = 48). </plain></SENT>
<SENT sid="428" pm="."><plain>Representative dot plots from one participant. </plain></SENT>
</text></p><p><text><SENT sid="429" pm="."><plain>(EPS) </plain></SENT>
</text></p></caption><media xlink:href="ppat.1005761.s002.eps"><caption><p><text><SENT sid="430" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1005761.s003"><label>S2 Fig</label><caption><title><text><SENT sid="431" pm="."><plain>Contribution of ICs expressing cells to the HIV reservoir pool. </plain></SENT>
</text></title><p><text><SENT sid="432" pm="."><plain>The contribution of cells expressing PD-1 (A), TIGIT (B) or LAG-3 (C) to the total HIV reservoir by taking into account the frequency of these subsets within the CD4 compartment and their relative infection frequencies (n = 12, n = 9 and n = 7, respectively). </plain></SENT>
<SENT sid="433" pm="."><plain>Horizontal bars indicate median values. </plain></SENT>
</text></p><p><text><SENT sid="434" pm="."><plain>(EPS) </plain></SENT>
</text></p></caption><media xlink:href="ppat.1005761.s003.eps"><caption><p><text><SENT sid="435" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1005761.s004"><label>S3 Fig</label><caption><title><text><SENT sid="436" pm="."><plain>Frequency of memory CD4+ T cells harboring integrated HIV DNA in PD-1/TIGIT/LAG-3 triple–(LPT-), PD-1 single + (P), TIGIT single + (T), LAG-3 single + (L), PD-1/TIGIT double + (PT), TIGIT/LAG-3 double + (LT), PD-1/LAG-3 double + (LP) and PD-1/TIGIT/LAG-3 triple + (LPT+) cells. </plain></SENT>
</text></title><p><text><SENT sid="437" pm="."><plain>Raw data from the 5 subjects presented in Fig 4B. </plain></SENT>
</text></p><p><text><SENT sid="438" pm="."><plain>(EPS) </plain></SENT>
</text></p></caption><media xlink:href="ppat.1005761.s004.eps"><caption><p><text><SENT sid="439" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1005761.s005"><label>S4 Fig</label><caption><title><text><SENT sid="440" pm="."><plain>PD-1, TIGIT and LAG-3 are associated with markers of activation/proliferation. </plain></SENT>
</text></title><p><text><SENT sid="441" pm="."><plain>(A), (B), (C) Associations between the current CD4+ T cell counts and the frequency of CD4+ T cells expressing PD-1, TIGIT and LAG-3, respectively. </plain></SENT>
<SENT sid="442" pm="."><plain>P, r values were obtained from Spearman’s ranked analysis. </plain></SENT>
<SENT sid="443" pm="."><plain>(D), (E) Associations between the frequency of CD4+ T cells co-expressing PD-1, TIGIT and LAG-3 and the frequencies of CD4+ T cells expression HLA-DR/CD38 and Ki67 respectively. </plain></SENT>
<SENT sid="444" pm="."><plain>P, r values were obtained from Spearman’s ranked analysis. </plain></SENT>
</text></p><p><text><SENT sid="445" pm="."><plain>(EPS) </plain></SENT>
</text></p></caption><media xlink:href="ppat.1005761.s005.eps"><caption><p><text><SENT sid="446" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1005761.s006"><label>S1 Table</label><caption><title><text><SENT sid="447" pm="."><plain>Virological markers of HIV persistence. </plain></SENT>
</text></title><p><text><SENT sid="448" pm="."><plain>(DOCX) </plain></SENT>
</text></p></caption><media xlink:href="ppat.1005761.s006.docx"><caption><p><text><SENT sid="449" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1005761.s007"><label>S2 Table</label><caption><title><text><SENT sid="450" pm="."><plain>Negative binomial regression models to assess the relationship between Total HIV DNA and Immune Checkpoints expression on CD4+ T cells. </plain></SENT>
</text></title><p><text><SENT sid="451" pm="."><plain>(DOCX) </plain></SENT>
</text></p></caption><media xlink:href="ppat.1005761.s007.docx"><caption><p><text><SENT sid="452" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1005761.s008"><label>S3 Table</label><caption><title><text><SENT sid="453" pm="."><plain>Negative binomial regression models to assess the relationship between 2-LTR circles and Immune Checkpoints expression on CD4+ T cells. </plain></SENT>
</text></title><p><text><SENT sid="454" pm="."><plain>(DOCX) </plain></SENT>
</text></p></caption><media xlink:href="ppat.1005761.s008.docx"><caption><p><text><SENT sid="455" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1005761.s009"><label>S4 Table</label><caption><title><text><SENT sid="456" pm="."><plain>Negative binomial regression models to assess the relationship between cell-associated US HIV RNA and Immune Checkpoints expression on CD4+ T cells. </plain></SENT>
</text></title><p><text><SENT sid="457" pm="."><plain>(DOCX) </plain></SENT>
</text></p></caption><media xlink:href="ppat.1005761.s009.docx"><caption><p><text><SENT sid="458" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1005761.s010"><label>S5 Table</label><caption><title><text><SENT sid="459" pm="."><plain>Negative binomial regression models to compare integrated HIV DNA in cells expressing the Immune Checkpoint Molecule with integrated HIV DNA in cells not expressing the Immune Checkpoint Molecule. </plain></SENT>
</text></title><p><text><SENT sid="460" pm="."><plain>(DOCX) </plain></SENT>
</text></p></caption><media xlink:href="ppat.1005761.s010.docx"><caption><p><text><SENT sid="461" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1005761.s011"><label>S6 Table</label><caption><title><text><SENT sid="462" pm="."><plain>Frequencies of ICs on CD4+ T cells in cohort 1 (n = 48). </plain></SENT>
</text></title><p><text><SENT sid="463" pm="."><plain>(DOCX) </plain></SENT>
</text></p></caption><media xlink:href="ppat.1005761.s011.docx"><caption><p><text><SENT sid="464" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="465" pm="."><plain>The authors thank the participants who have generously donated samples for this study as well as the Clinical Core at UCSF for patient recruitment and specimen collection. </plain></SENT>
<SENT sid="466" pm="."><plain>The authors thank Patrick Yeramian, Moti Ramgopal, Rebeka Bordi, Brenda Jacobs, and Kathyrin Penniman for recruitment and clinical assistance with study participants and Amanda McNulty and Stephanie Santos for technical assistance. </plain></SENT>
<SENT sid="467" pm="."><plain>We also thank the flow cores at UCSF, at VGTI Florida (Yu Shi and Kim Kusser) and at CRCHUM (Dominique Gauchat and Annie Gosselin) for cell sorting. </plain></SENT>
<SENT sid="468" pm="."><plain>The authors thank Marta Massanella and the members of the Cleveland Immunopathogenesis Consortium for advice and helpful discussions. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list><title>References</title><ref id="ppat.1005761.ref001"><text><SENT sid="469" pm="."><plain>1 PerelsonAS, EssungerP, CaoY, VesanenM, HurleyA, SakselaK, et al Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997;387: 188–191. <?supplied-pmid 9144290?>9144290 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref002"><text><SENT sid="470" pm="."><plain>2 PalellaFJ, DelaneyKM, MoormanAC, LovelessMO, FuhrerJ, SattenGA, et al Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. </plain></SENT>
<SENT sid="471" pm="."><plain>HIV Outpatient Study Investigators. N Engl J Med. 1998;338: 853–860. <?supplied-pmid 9516219?>9516219 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref003"><text><SENT sid="472" pm="."><plain>3 DaveyRT, BhatN, YoderC, ChunTW, MetcalfJA, DewarR, et al HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A. 1999;96: 15109–15114. <?supplied-pmid 10611346?>10611346 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref004"><text><SENT sid="473" pm="."><plain>4 ChunT-W, JustementJS, MurrayD, HallahanCW, MaenzaJ, CollierAC, et al Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS. 2010;24: 2803–2808. 10.1097/QAD.0b013e328340a239 <?supplied-pmid 20962613?>20962613 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref005"><text><SENT sid="474" pm="."><plain>5 International AIDS Society Scientific Working Group on HIV Cure, DeeksSG, AutranB, BerkhoutB, BenkiraneM, CairnsS, et al Towards an HIV cure: a global scientific strategy. </plain></SENT>
<SENT sid="475" pm="."><plain>Nature Publishing Group. 2012;12: 607–614. </plain></SENT>
</text></ref><ref id="ppat.1005761.ref006"><text><SENT sid="476" pm="."><plain>6 ChomontN, El-FarM, AncutaP, TrautmannL, ProcopioFA, Yassine-DiabB, et al HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. </plain></SENT>
<SENT sid="477" pm="."><plain>Nature Publishing Group. </plain></SENT>
<SENT sid="478" pm="."><plain>Nature Publishing Group; 2009;: 1–9. </plain></SENT>
</text></ref><ref id="ppat.1005761.ref007"><text><SENT sid="479" pm="."><plain>7 BuzonMJ, SunH, LiC, ShawA, SeissK, OuyangZ, et al HIV-1 persistence in CD4+ T cells with stem cell-like properties. Nature Medicine. 2014;20: 139–142. 10.1038/nm.3445 <?supplied-pmid 24412925?>24412925 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref008"><text><SENT sid="480" pm="."><plain>8 JaafouraS, de Goër de HerveMG, Hernandez-VargasEA, Hendel-ChavezH, AbdohM, MateoMC, et al Progressive contraction of the latent HIV reservoir around a core of less-differentiated CD4⁺ memory T Cells. Nat Commun. 2014;5: 5407 10.1038/ncomms6407 <?supplied-pmid 25382623?>25382623 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref009"><text><SENT sid="481" pm="."><plain>9 GosselinA, MonteiroP, ChomontN, Diaz-GrifferoF, SaidEA, FonsecaS, et al Peripheral blood CCR4+CCR6+ and CXCR3+CCR6+CD4+ T cells are highly permissive to HIV-1 infection. J Immunol. 2010;184: 1604–1616. 10.4049/jimmunol.0903058 <?supplied-pmid 20042588?>20042588 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref010"><text><SENT sid="482" pm="."><plain>10 MonteiroP, GosselinA, WaclecheVS, El-FarM, SaidEA, KaredH, et al Memory CCR6+CD4+ T Cells Are Preferential Targets for Productive HIV Type 1 Infection Regardless of Their Expression of Integrin {beta}7. J Immunol. 2011;186: 4618–4630. 10.4049/jimmunol.1004151 <?supplied-pmid 21398606?>21398606 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref011"><text><SENT sid="483" pm="."><plain>11 SunH, KimD, LiX, KiselinovaM, OuyangZ, VandekerckhoveL, et al Th1/17 Polarization of CD4 T Cells Supports HIV-1 Persistence during Antiretroviral Therapy. J Virol. 2015;89: 11284–11293. 10.1128/JVI.01595-15 <?supplied-pmid 26339043?>26339043 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref012"><text><SENT sid="484" pm="."><plain>12 KhouryG, AndersonJL, FromentinR, HartogensisW, SmithMZ, BacchettiP, et al Persistence of integrated HIV DNA in CXCR3 + CCR6 + memory CD4+ T-cells in HIV-infected individuals on antiretroviral therapy. AIDS. 2016;Publish Ahead of Print: 1. </plain></SENT>
</text></ref><ref id="ppat.1005761.ref013"><text><SENT sid="485" pm="."><plain>13 GreenwaldRJ, FreemanGJ, SharpeAH. The B7 family revisited. Annu Rev Immunol. 2005;23: 515–548. <?supplied-pmid 15771580?>15771580 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref014"><text><SENT sid="486" pm="."><plain>14 TrautmannL, JanbazianL, ChomontN, SaidEA, GimmigS, BessetteB, et al Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nature Medicine. 2006;12: 1198–1202. <?supplied-pmid 16917489?>16917489 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref015"><text><SENT sid="487" pm="."><plain>15 DayCL, KaufmannDE, KiepielaP, BrownJA, MoodleyES, ReddyS, et al PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006;443: 350–354. <?supplied-pmid 16921384?>16921384 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref016"><text><SENT sid="488" pm="."><plain>16 PetrovasC, CasazzaJP, BrenchleyJM, PriceDA, GostickE, AdamsWC, et al PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med. 2006;203: 2281–2292. <?supplied-pmid 16954372?>16954372 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref017"><text><SENT sid="489" pm="."><plain>17 PorichisF, KwonDS, ZupkoskyJ, TigheDP, McMullenA, BrockmanMA, et al Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood. 2011;118: 965–974. 10.1182/blood-2010-12-328070 <?supplied-pmid 21652684?>21652684 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref018"><text><SENT sid="490" pm="."><plain>18 FreemanGJ, LongAJ, IwaiY, BourqueK, ChernovaT, NishimuraH, et al Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192: 1027–1034. <?supplied-pmid 11015443?>11015443 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref019"><text><SENT sid="491" pm="."><plain>19 CarterL, FouserLA, JussifJ, FitzL, DengB, WoodCR, et al PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol. 2002;32: 634–643. <?supplied-pmid 11857337?>11857337 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref020"><text><SENT sid="492" pm="."><plain>20 D'SouzaM, FontenotAP, MackDG, LozuponeC, DillonS, MeditzA, et al Programmed death 1 expression on HIV-specific CD4+ T cells is driven by viral replication and associated with T cell dysfunction. J Immunol. 2007;179: 1979–1987. <?supplied-pmid 17641065?>17641065 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref021"><text><SENT sid="493" pm="."><plain>21 CockerhamLR, JainV, SinclairE, GliddenDV, HartogenesisW, HatanoH, et al Programmed death-1 expression on CD4+ and CD8+ T cells in treated and untreated HIV disease. AIDS. 2014;28: 1749–1758. 10.1097/QAD.0000000000000314 <?supplied-pmid 24871455?>24871455 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref022"><text><SENT sid="494" pm="."><plain>22 LevinSD, TaftDW, BrandtCS, BucherC, HowardED, ChadwickEM, et al Vstm3 is a member of the CD28 family and an important modulator of T-cell function. Eur J Immunol. 2011;41: 902–915. 10.1002/eji.201041136 <?supplied-pmid 21416464?>21416464 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref023"><text><SENT sid="495" pm="."><plain>23 YuX, HardenK, GonzalezLC, FrancescoM, ChiangE, IrvingB, et al The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nature Immunology. 2009;10: 48–57. 10.1038/ni.1674 <?supplied-pmid 19011627?>19011627 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref024"><text><SENT sid="496" pm="."><plain>24 ChewGM, FujitaT, WebbGM, BurwitzBJ, WuHL, ReedJS, et al TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection. PLoS Pathog. 2016;12: e1005349 10.1371/journal.ppat.1005349 <?supplied-pmid 26741490?>26741490 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref025"><text><SENT sid="497" pm="."><plain>25 YamamotoT, PriceDA, CasazzaJP, FerrariG, NasonM, ChattopadhyayPK, et al Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection. Blood. 2011;117: 4805–4815. 10.1182/blood-2010-11-317297 <?supplied-pmid 21398582?>21398582 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref026"><text><SENT sid="498" pm="."><plain>26 HuardB, MastrangeliR, PrigentP, BruniquelD, DoniniS, El-TayarN, et al Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proc Natl Acad Sci U S A. 1997;94: 5744–5749. <?supplied-pmid 9159144?>9159144 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref027"><text><SENT sid="499" pm="."><plain>27 HuangC-T, WorkmanCJ, FliesD, PanX, MarsonAL, ZhouG, et al Role of LAG-3 in regulatory T cells. Immunity. 2004;21: 503–513. <?supplied-pmid 15485628?>15485628 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref028"><text><SENT sid="500" pm="."><plain>28 WorkmanCJ, VignaliDAA. Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223). J Immunol. 2005;174: 688–695. <?supplied-pmid 15634887?>15634887 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref029"><text><SENT sid="501" pm="."><plain>29 JonesRB, NdhlovuLC, BarbourJD, ShethPM, JhaAR, LongBR, et al Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med. 2008;205: 2763–2779. 10.1084/jem.20081398 <?supplied-pmid 19001139?>19001139 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref030"><text><SENT sid="502" pm="."><plain>30 KassuA, MarcusRA, D'SouzaMB, Kelly-McKnightEA, Golden-MasonL, AkkinaR, et al Regulation of virus-specific CD4+ T cell function by multiple costimulatory receptors during chronic HIV infection. J Immunol. 2010;185: 3007–3018. 10.4049/jimmunol.1000156 <?supplied-pmid 20656923?>20656923 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref031"><text><SENT sid="503" pm="."><plain>31 CaiG, AnumanthanA, BrownJA, GreenfieldEA, ZhuB, FreemanGJ. CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator. Nature Immunology. 2008;9: 176–185. 10.1038/ni1554 <?supplied-pmid 18193050?>18193050 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref032"><text><SENT sid="504" pm="."><plain>32 PeretzY, HeZ, ShiY, Yassine-DiabB, GouletJ-P, BordiR, et al CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction. PLoS Pathog. 2012;8: e1002840 10.1371/journal.ppat.1002840 <?supplied-pmid 22916009?>22916009 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref033"><text><SENT sid="505" pm="."><plain>33 KaplanRC, SinclairE, LandayAL, LurainN, SharrettAR, GangeSJ, et al T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis. 2011;203: 452–463. 10.1093/infdis/jiq071 <?supplied-pmid 21220772?>21220772 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref034"><text><SENT sid="506" pm="."><plain>34 VandergeetenC, FromentinR, MerliniE, LawaniMB, DaFonsecaS, BakemanW, et al Cross-clade ultrasensitive PCR-based assays to measure HIV persistence in large-cohort studies. J Virol. 2014;88: 12385–12396. 10.1128/JVI.00609-14 <?supplied-pmid 25122785?>25122785 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref035"><text><SENT sid="507" pm="."><plain>35 ElliottJH, McMahonJH, ChangCC, LeeSA, HartogensisW, BumpusN, et al Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. Lancet HIV. 2015;2: e520–9. 10.1016/S2352-3018(15)00226-X <?supplied-pmid 26614966?>26614966 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref036"><text><SENT sid="508" pm="."><plain>36 ProcopioFA, FromentinR, KulpaDA, BrehmJH, BebinA-G, StrainMC, et al A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals. EBioMedicine. 2015;2: 872–881. </plain></SENT>
</text></ref><ref id="ppat.1005761.ref037"><text><SENT sid="509" pm="."><plain>37 BoulasselM-R, ChomontN, PaiNP, GilmoreN, SékalyR-P, RoutyJ-P. CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy. J Clin Virol. 2012;53: 29–32. 10.1016/j.jcv.2011.09.018 <?supplied-pmid 22019250?>22019250 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref038"><text><SENT sid="510" pm="."><plain>38 ChunT-W, JustementJS, PandyaP, HallahanCW, McLaughlinM, LiuS, et al Relationship between the size of the human immunodeficiency virus type 1 (HIV-1) reservoir in peripheral blood CD4+ T cells and CD4+:CD8+ T cell ratios in aviremic HIV-1-infected individuals receiving long-term highly active antiretroviral therapy. J Infect Dis. 2002;185: 1672–1676. <?supplied-pmid 12023777?>12023777 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref039"><text><SENT sid="511" pm="."><plain>39 MorouA, PalmerBE, KaufmannDE. Distinctive features of CD4+ T cell dysfunction in chronic viral infections. Curr Opin HIV AIDS. 2014;9: 446–451. 10.1097/COH.0000000000000094 <?supplied-pmid 25023623?>25023623 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref040"><text><SENT sid="512" pm="."><plain>40 HoY-C, ShanL, HosmaneNN, WangJ, LaskeySB, RosenbloomDIS, et al Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell. 2013;155: 540–551. 10.1016/j.cell.2013.09.020 <?supplied-pmid 24243014?>24243014 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref041"><text><SENT sid="513" pm="."><plain>41 HatanoH, JainV, HuntPW, LeeT-H, SinclairE, DoTD, et al Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. J Infect Dis. 2013;208: 50–56. 10.1093/infdis/jis630 <?supplied-pmid 23089590?>23089590 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref042"><text><SENT sid="514" pm="."><plain>42 YuklSA, ShergillAK, GirlingV, LiQ, KillianM, EplingL, et al Site-specific differences in T cell frequencies and phenotypes in the blood and gut of HIV-uninfected and ART-treated HIV+ adults. PLoS ONE. 2015;10: e0121290 10.1371/journal.pone.0121290 <?supplied-pmid 25811360?>25811360 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref043"><text><SENT sid="515" pm="."><plain>43 HurstJ, HoffmannM, PaceM, WilliamsJP, ThornhillJ, HamlynE, et al Immunological biomarkers predict HIV-1 viral rebound after treatment interruption. Nat Commun. 2015;6: 8495 10.1038/ncomms9495 <?supplied-pmid 26449164?>26449164 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref044"><text><SENT sid="516" pm="."><plain>44 ValiathanR, MiguezMJ, PatelB, ArheartKL, AsthanaD. Tobacco smoking increases immune activation and impairs T-cell function in HIV infected patients on antiretrovirals: a cross-sectional pilot study. PLoS ONE. 2014;9: e97698 10.1371/journal.pone.0097698 <?supplied-pmid 24842313?>24842313 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref045"><text><SENT sid="517" pm="."><plain>45 BlackburnSD, ShinH, HainingWN, ZouT, WorkmanCJ, PolleyA, et al Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nature Immunology. 2009;10: 29–37. 10.1038/ni.1679 <?supplied-pmid 19043418?>19043418 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref046"><text><SENT sid="518" pm="."><plain>46 GrossoJF, GoldbergMV, GetnetD, BrunoTC, YenH-R, PyleKJ, et al Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol. 2009;182: 6659–6669. 10.4049/jimmunol.0804211 <?supplied-pmid 19454660?>19454660 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref047"><text><SENT sid="519" pm="."><plain>47 MatsuzakiJ, GnjaticS, Mhawech-FaucegliaP, BeckA, MillerA, TsujiT, et al Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A. 2010;107: 7875–7880. 10.1073/pnas.1003345107 <?supplied-pmid 20385810?>20385810 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref048"><text><SENT sid="520" pm="."><plain>48 BaitschL, LegatA, BarbaL, Fuertes MarracoSA, RivalsJ-P, BaumgaertnerP, et al Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS ONE. 2012;7: e30852 10.1371/journal.pone.0030852 <?supplied-pmid 22347406?>22347406 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref049"><text><SENT sid="521" pm="."><plain>49 WooS-R, TurnisME, GoldbergMV, BankotiJ, SelbyM, NirschlCJ, et al Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72: 917–927. 10.1158/0008-5472.CAN-11-1620 <?supplied-pmid 22186141?>22186141 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref050"><text><SENT sid="522" pm="."><plain>50 ChauvinJ-M, PaglianoO, FourcadeJ, SunZ, WangH, SanderC, et al TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients. J Clin Invest. 2015;125: 2046–2058. 10.1172/JCI80445 <?supplied-pmid 25866972?>25866972 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref051"><text><SENT sid="523" pm="."><plain>51 WightmanF, SolomonA, KumarSS, UrriolaN, GallagherK, HienerB, et al Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma. AIDS. 2015;29: 504–506. 10.1097/QAD.0000000000000562 <?supplied-pmid 25628259?>25628259 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref052"><text><SENT sid="524" pm="."><plain>52 RomanoE, Kusio-KobialkaM, FoukasPG, BaumgaertnerP, MeyerC, BallabeniP, et al Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci U S A. 2015;112: 6140–6145. 10.1073/pnas.1417320112 <?supplied-pmid 25918390?>25918390 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref053"><text><SENT sid="525" pm="."><plain>53 BacchettiP. Peer review of statistics in medical research: the other problem. BMJ. 2002;324: 1271–1273. <?supplied-pmid 12028986?>12028986 </plain></SENT>
</text></ref><ref id="ppat.1005761.ref054"><text><SENT sid="526" pm="."><plain>54 ErikssonS, GrafEH, DahlV, StrainMC, YuklSA, LysenkoES, et al Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog. 2013;9: e1003174 10.1371/journal.ppat.1003174 <?supplied-pmid 23459007?>23459007 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
